ORKA-001
Sponsors
Oruka Therapeutics Inc., Oruka Therapeutics, Inc.
Conditions
Healthy VolunteersModerate-to-Severe Plaque PsoriasisPlaque Psoriasis
Phase 1
Phase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Active, not recruitingNCT07290569
Start: 2025-12-03End: 2028-12-01Target: 160Updated: 2026-08-17
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RecruitingNCT07449702
Start: 2026-02-23End: 2030-07-01Target: 240Updated: 2026-09-04
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
Not yet recruitingCTIS2025-523797-17-00
Target: 16Updated: 2026-05-08